Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

QbCheck

Child drawing image with crayon

Making the shortlist for patient engagement and communications

Grace Communications has been shortlisted this year in both the PMi Awards and the Creative Floor Awards for an engaging creative campaign, putting patients at the forefront.

Grace Communications

Mobilizing Agitation Detection in Children with ADHD

Marius Rus, founder of StressLess–the startup behind Tully–discusses wearable technologies for children with ADHD, autism, and other mental health conditions. He also shares his tips and lessons learned from founding...

Impetus Digital

Mobilizing Agitation Detection in Children with ADHD

Marius Rus, founder of StressLess–the startup behind Tully–discusses wearable technologies for children with ADHD, autism, and other mental health conditions. He also shares his tips and lessons learned from founding...

Impetus Digital

Neurodiversity, ADHD and work: Obstacles and opportunities

For ADHD awareness month this year our Associate Medical Writer, Alex Teahan, has written a piece surrounding ADHD and employment. He discusses the advantages and disadvantages of ADHD at work,...

Mednet

- PMLiVE

Shire separates out neuroscience as it considers its future

Follows last year's strategic review at the Irish biotechnology firm

- PMLiVE

Akili to submit video game ADHD treatment for US approval in 2018

Follows trial suggesting attention benefits of its 'digital medicine' AKL-T01

- PMLiVE

Shire claims FDA approval for slow-cooked ADHD drug

Mydayis will reach the US market in the third quarter of the year

- PMLiVE

First online ADHD treatment test launched in the US

Qbtech brings its QbCheck assessment to market after winning FDA approval

Shire Basingstoke

Shire launches long-acting ADHD drug Intuniv in UK

Also plans to launch the once-daily treatment in Japan later this year

- PMLiVE

Challenging perceptions

Alvaro Herreros on the ADHD landscape

Shire Basingstoke

Shire wins EU approval for prolonged-release ADHD drug

First treatment in its class to be licensed for ADHD in Europe

Shire Basingstoke

Shire pitching at adult ADHD product launch in 2017

Will have to first trial formulation in children to appease FDA

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links